Seek Returns

KYMR vs. SMMT: Kymera Therapeutics vs. Summit Therapeutics Stock Comparison

How do Kymera Therapeutics (KYMR) and Summit Therapeutics (SMMT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Kymera Therapeutics (KYMR) and Summit Therapeutics (SMMT) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Kymera Therapeutics (KYMR) and Summit Therapeutics (SMMT)
Profile ItemKYMRSMMT
NameKymera Therapeutics Inc.Summit Therapeutics Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization11.25 billion USD13.06 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateAugust 21, 2020March 5, 2015
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

KYMR
SMMT
GSPC
Loading price history…
Kymera Therapeutics (KYMR) vs. Summit Therapeutics (SMMT), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Kymera Therapeutics (KYMR) and Summit Therapeutics (SMMT). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Kymera Therapeutics (KYMR) and Summit Therapeutics (SMMT). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Kymera Therapeutics (KYMR) and Summit Therapeutics (SMMT)
MetricKYMRSMMT
Total Return (1Y)131.52%-2.48%
Total Return (3Y, Annualized)111.65%116.18%
Total Return (5Y, Annualized)15.68%26.89%

Risk Profile

Drawdown History

KYMR
SMMT
GSPC
Loading price history…
Kymera Therapeutics (KYMR) vs. Summit Therapeutics (SMMT), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Kymera Therapeutics (KYMR) and Summit Therapeutics (SMMT). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Kymera Therapeutics (KYMR) has a non-negative beta of 2.00.

Risk profile metrics for Kymera Therapeutics (KYMR) and Summit Therapeutics (SMMT)
MetricKYMRSMMT
Volatility (1Y, Annualized)62.83%75.06%
Beta (5Y)2.00-1.51
Max Drawdown (5Y)-83.27%-87.64%
Avg. Volume (3M)833.05K6.19M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
KYMR and SMMT are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Kymera Therapeutics (KYMR) and Summit Therapeutics (SMMT)
MetricKYMRSMMT
Sharpe Ratio (1Y)2.03-0.09
Sortino Ratio (1Y)4.16-0.13

Profitability

ROE (TTM)

Both Kymera Therapeutics (KYMR) at -27.29% and Summit Therapeutics (SMMT) at -220.01% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-27.29%

Max
109.18%
Q3
6.23%
Median
-26.66%
KYMR
-27.29%
Q1
-64.05%
Min
-167.77%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

-220.01%

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
SMMT
-220.01%
Loading chart…
Kymera Therapeutics (KYMR) vs. Summit Therapeutics (SMMT): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Kymera Therapeutics (KYMR) at 0.00% and Summit Therapeutics (SMMT) at 0.00% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
KYMR
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
SMMT
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Kymera Therapeutics (KYMR) vs. Summit Therapeutics (SMMT): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Summit Therapeutics (SMMT) reports 0.00%, ranking against industry peers normally.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-396.04%

Max
83.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
KYMR
-396.04%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
SMMT
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Kymera Therapeutics (KYMR) vs. Summit Therapeutics (SMMT): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Kymera Therapeutics (KYMR) and Summit Therapeutics (SMMT)
MetricKYMRSMMT
ROE (TTM)-27.29%-220.01%
ROA (TTM)-17.64%-111.99%
Net Margin (TTM)0.00%0.00%
Operating Margin (TTM)-396.04%0.00%
Gross Margin (TTM)0.00%0.00%

Growth

Revenue Growth

Only one side can be read here: Kymera Therapeutics (KYMR) reports revenue growth of -16.70%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Loading chart…
Kymera Therapeutics (KYMR) vs. Summit Therapeutics (SMMT): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Kymera Therapeutics (KYMR) nor Summit Therapeutics (SMMT) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Kymera Therapeutics (KYMR) and Summit Therapeutics (SMMT)
MetricKYMRSMMT
Revenue Growth (YoY)-16.70%--
Revenue Growth (3Y CAGR)-5.74%--
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Both Kymera Therapeutics (KYMR) at 11.13 and Summit Therapeutics (SMMT) at 5.99 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.13

Max
25.13
Q3
12.13
KYMR
11.13
Median
5.52
Q1
2.47
Min
0.10

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.99

Max
25.13
Q3
12.13
SMMT
5.99
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
Kymera Therapeutics (KYMR) vs. Summit Therapeutics (SMMT): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Kymera Therapeutics (KYMR) at 0.05 and Summit Therapeutics (SMMT) at 0.04 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.05

Max
1.42
Q3
0.65
Median
0.15
KYMR
0.05
Q1
0.02
Min
0.00

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.04

Max
1.42
Q3
0.65
Median
0.15
SMMT
0.04
Q1
0.02
Min
0.00
Loading chart…
Kymera Therapeutics (KYMR) vs. Summit Therapeutics (SMMT): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Kymera Therapeutics (KYMR) and Summit Therapeutics (SMMT)
MetricKYMRSMMT
Current Ratio (MRQ)11.135.99
Debt / Equity (MRQ)0.050.04
Net Debt / EBITDA----

Dividends

Dividend Yield (TTM)

Neither Kymera Therapeutics (KYMR) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SMMT
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Kymera Therapeutics (KYMR) vs. Summit Therapeutics (SMMT): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Kymera Therapeutics (KYMR) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SMMT
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Kymera Therapeutics (KYMR) vs. Summit Therapeutics (SMMT): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Kymera Therapeutics (KYMR) and Summit Therapeutics (SMMT)
MetricKYMRSMMT
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Neither Kymera Therapeutics (KYMR) nor Summit Therapeutics (SMMT) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
KYMR
--

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
SMMT
--
Loading chart…
Kymera Therapeutics (KYMR) vs. Summit Therapeutics (SMMT): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

A sales-based read is only available for Kymera Therapeutics (KYMR), whose P/S ratio of 110.00 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

110.00

KYMR
110.00
Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
SMMT
--
Loading chart…
Kymera Therapeutics (KYMR) vs. Summit Therapeutics (SMMT): SMMT does not report P/S ratio, so it has no value marker; KYMR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

Both look rich against book: Kymera Therapeutics (KYMR) at 6.96 sits in the upper P/B ratio quartile, and Summit Therapeutics (SMMT) at 23.13 prices even higher, above its industry range.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.96

Max
13.53
KYMR
6.96
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.13

SMMT
23.13
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Kymera Therapeutics (KYMR) vs. Summit Therapeutics (SMMT): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Kymera Therapeutics (KYMR) and Summit Therapeutics (SMMT)
MetricKYMRSMMT
P/E Ratio (TTM)----
P/S Ratio (TTM)110.00--
P/B Ratio (MRQ)6.9623.13
Free Cash Flow Yield (TTM)-1.46%-1.64%